Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “dopamine”

37 pharma patents match "dopamine" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 37
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 37 pharmaceutical patents matching "dopamine" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

37 results for “dopamine” · 30,257 patents in full index Clear search

  1. US 12162861

    Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted

  2. US 12145922

    Selective D3 dopamine receptor agonists and methods of their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted

  3. US 12102640

    Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted

  4. US 12097196

    Dopamine D3 receptor selective antagonists/partial agonists and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted

  5. US 11634404

    Selective D3 dopamine receptor agonists and methods of their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  6. US 11337971

    Dopamine D3 receptor selective antagonists/partial agonists and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 24, 2022 · Expires May 19, 2042

    granted

  7. US 11299476

    Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted

  8. US 11261461

    Methods and compositions for selective generation of dopaminergic precursors

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted

  9. US 11033554

    Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration

    United States Government as represented by the Department of Veterans Affairs · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  10. WO 2020246903

    INHIBITEURS DE DOPAMINE-B-HYDROXYLASE

    BIAL PORTELA & Cª S A [PT] · Granted Dec 10, 2020 · Expires Dec 5, 2040

    granted

  11. CA 3142348

    INHIBITEURS DE DOPAMINE-B-HYDROXYLASE

    BIAL PORTELA & CA SA [PT] · Granted Dec 10, 2020 · Expires Dec 5, 2040

    granted

  12. AU 2018379646

    Dopamine-B-hydroxylase inhibitors

    BIAL PORTELA & Cª S A [PT] · Granted Jun 11, 2020 · Expires Jun 6, 2040

    granted

  13. US 10654842

    Dopamine D3 receptor antagonist compounds

    Indivior UK Limited · Granted May 19, 2020 · Expires May 14, 2040

    granted

  14. US 10577361

    Dopamine D3 receptor antagonists having a morpholine moiety

    Indivior UK Limited · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted

  15. CA 3103212

    FORMULATIONS COMPRENANT DES INHIBITEURS DE LA DOPAMINE-S-HYDROXYLASE ET LEURS PROCEDES DE PREPARATION

    BIAL PORTELA & CA SA [PT] · Granted Jan 2, 2020 · Expires Dec 28, 2039

    granted

  16. US 2019337950

    BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS

    BIAL PORTELA & Cª S A [PT] · Granted Nov 7, 2019 · Expires Nov 2, 2039

    granted

  17. CA 3082337

    INHIBITEURS DE DOPAMINE-B-HYDROXYLASE

    BIAL PORTELA & CA SA [PT] · Granted Jun 13, 2019 · Expires Jun 8, 2039

    granted

  18. US 10273244

    Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators

    Indivior UK Limited · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  19. US 10239870

    Dopamine D3 receptor antagonists

    Indivior UK Limited · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  20. US 10016499

    Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same

    Northwestern University · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  21. US 10017734

    Method for producing dopaminergic neurons

    Takeda Pharmaceutical Company Limited · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  22. US 10000477

    Dopamine D3 receptor antagonist compounds

    Indivior UK Limited · Granted Jun 19, 2018 · Expires Jun 14, 2038

    granted

  23. US 9828352

    Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR)

    The Regents of the University of California · Granted Nov 28, 2017 · Expires Nov 23, 2037

    granted

  24. US 9550742

    11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 24, 2017 · Expires Jan 19, 2037

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.